InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: inmodemd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham | |
| 12/21/2022 | $44.00 | Overweight | Barclays |
| 10/12/2022 | $40.00 | Buy | Jefferies |
| 2/11/2022 | $103.00 → $82.00 | Buy | Needham |
| 10/27/2021 | $80.00 → $100.00 | Buy | Canaccord Genuity |
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
20-F - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights: Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024).Quarterly revenues from consumables and service of $15.8 million, a decrease of 11% compared to the third quarter of 2023.GAAP operation income of $48.2 million, *non-GAAP operation income of $52.2 million.Total cash position of $684.9 million as of September 30, 2024
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 before the Nasdaq market opens on Wednesday, October 30, 2024. InMode is
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (includin
Believes InMode's Cash Balance of Roughly 55% of its Market Cap is Grossly Inefficient Asserts the Current Valuation Offers an Unprecedented Opportunity to Create Shareholder Return MIAMI, July 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of InMode (NYSE: INMD) urging the Board to execute a 40% tender offer of the stock. The letter can be downloaded here. The full text of the letter follows: July 25, 2024 To the Board Members of InMode: DOMA Perpetual Capital Management is an asset manager focused on generating l
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M Conference call to be held on Thursday, Aug. 1, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, July 11, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2024 before the Nasdaq market opens on Thursday, Aug. 1, 2024. InMode is currently finalizing its financial res
Company Announces Share Repurchase Program of Up to 8.37 Million Shares; and Appoints New Chairman of the Board of Directors YOKNEAM, Israel, May 2, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: Quarterly GAAP revenue of $80.3 million, a decrease of 24% compared to the first quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 84% of its quarterly revenues, while 11% were derived from InMode's traditiona
Expects Q1 Revenue Between $80.0M-$80.1M, Pro Forma Revenue (including new platform pre-orders) Between $95.7M- $95.8M, Decreases FY 2024 Guidance to $485M-$495M Conference call to be held on Thursday, May 2, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 9, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024. InMode is currently finalizing its financial results for the first quarter of 2024. While complete financial information and operating data are not yet available, set
YOKNEAM, Israel, Feb. 13, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Highlights: Quarterly revenue of $126.8 million, compared to $133.6 in the fourth quarter of 2022.Quarterly revenues from consumables and service of $20.5 million, an increase of 20% compared to the fourth quarter of 2022.Total cash position of $741.6 million as of December 31, 2023, including cash and cash equivalents, marketable securities, and short-term bank deposits.Full Year 2023 Highlights: Record full year r
Conference call to be held on Tuesday, February 13, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Jan. 16, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2023 before the Nasdaq market opens on Tuesday, February 13, 2024. InMode is currently finalizing its financial results for the fourth quarter and full year of 2023. While complete financial information and operating data are not yet available, set forth below are certain preliminary financial results for said period, subject to final adjustments and other developments that
Conference call to be held on Thursday, Nov. 2, 2023, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 12, 2023 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2023 before the Nasdaq market opens on Thursday, Nov. 2, 2023. InMode is currently finalizing its financial results for the three months ended Sept. 30, 2023. While complete financial information and operating data are not yet available, set forth below are certain preliminary financial results for such period, subject to final adjustments and further review as well as other developments t
YOKNEAM, Israel, Nov. 6, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in November and December: UBS Global Healthcare ConferencePresenters: Yair Malca, Chief Financial OfficerFormat: In-person fireside chat moderated by Danielle Antalffy, Senior Equity Analyst, and one-on-one meetingsLocation: Palos Verdes, CAWhen: Tuesday, Nov. 12 at 2:00 pm PTA live webcast of the presentation can be accessed here. Jefferies London Healthcare ConferencePresenters: Moshe Mizrahy, Chief Executive OfficerFormat: In-person fireside chat moderated by Matt Taylor, Senior Equit
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights: Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024).Quarterly revenues from consumables and service of $15.8 million, a decrease of 11% compared to the third quarter of 2023.GAAP operation income of $48.2 million, *non-GAAP operation income of $52.2 million.Total cash position of $684.9 million as of September 30, 2024
IRVINE, Calif., Oct. 24, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, has been granted a preliminary injunction by the U.S. District Court for the Central District of California in a lawsuit filed against sellers identified to be the source of unlawful counterfeit sales of Morpheus8 radiofrequency devices and cartridge accessories. On September 3, 2024, the Honorable Michael Fitzgerald of the U.S. District Court for the Central District of California issued the order granting InMode's motion for a preliminary in
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 before the Nasdaq market opens on Wednesday, October 30, 2024. InMode is
YOKNEAM, Israel, Oct. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies today announced the departure of Shakil Lakhani, President of North America effective September 30, 2024. His departure follows that of Dr. Spero Theodorou, Chief Medical Officer, and Dan Wilson, VP of Sales USA. In addition to the departure of the three executives from InMode's North American operations, over the last few months, InMode has changed the management teams in three of its subsidiaries in Europe: InMode UK, InMode Iberia and InMode
YOKNEAM, Israel, Sept. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that its Board of Directors has approved a share repurchase program of up to 7.68 million ordinary shares. "Following the completion of our share buyback program announced earlier this year, the board's authorization to enact this new share repurchase program demonstrates our ongoing confidence in the long-term outlook of the company," commented Moshe Mizrahy, InMode's Chief Executive Officer. "InMode continues to be profitab
YOKNEAM, Israel, Sept. 4, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present in-person at the 2024 Baird Global Healthcare Conference in New York on Sept. 10, 2024. The fireside chat, moderated by Jeff Johnson, Senior Research Analyst, is scheduled for 2:00 pm Eastern Time on Tuesday, Sept. 10, and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Baird representative. For more information about the event, visit InMode's investor relations
YOKNEAM, Israel, Aug. 6, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences and events in August: 9th Annual Needham Virtual MedTech & Diagnostics Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial OfficerFormat: Virtual one-on-one meetingsWhen: Monday, Aug. 12 Canaccord 44th Annual Global Growth Conference Presenters: Yair Malca, Chief Financial OfficerFormat: In-person fireside chat moderated by Caitlin
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (includin
IRVINE, Calif., July 31, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, is pleased to announce the introduction of IgniteRF, a ground-breaking minimally invasive workstation inclusive of nine technologies which offer soft tissue contraction across multiple tissue depths. The IgniteRF platform, alongside the BodyTite, FaceTite, Morpheus8, and now QuantumRF family of products offers a comprehensive suite of radiofrequency solutions for various aesthetic and surgical needs. QuantumRF is a new, advanced minimally invas
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
Jefferies downgraded InMode from Buy to Hold and set a new price target of $19.00 from $21.00 previously
UBS downgraded InMode from Buy to Neutral and set a new price target of $24.00 from $52.00 previously
Canaccord Genuity downgraded InMode from Buy to Hold and set a new price target of $22.00 from $55.00 previously
UBS initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham downgraded InMode from Buy to Hold
Barclays initiated coverage of InMode with a rating of Overweight and set a new price target of $44.00
Jefferies initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham reiterated coverage of InMode with a rating of Buy and set a new price target of $82.00 from $103.00 previously
Canaccord Genuity reiterated coverage of InMode with a rating of Buy and set a new price target of $100.00 from $80.00 previously
Jefferies analyst Matthew Taylor downgrades InMode (NASDAQ:INMD) from Buy to Hold and lowers the price target from $21 to $19.
Barclays analyst Matt Miksic maintains InMode (NASDAQ:INMD) with a Overweight and lowers the price target from $33 to $29.
Canaccord Genuity analyst Caitlin Cronin maintains InMode (NASDAQ:INMD) with a Hold and lowers the price target from $21 to $16.
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
Expects Q2 Revenue Between $86.2M-$86.3M, Pro-Forma Revenue (including new platform pre-orders) Between $102.4M-$102.5M, Decreases FY 2024 Guidance to $430M-$440M
Needham analyst Mike Matson reiterates InMode (NASDAQ:INMD) with a Hold.
InMode (NASDAQ:INMD) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.44 by 27.27 percent. This is a 38.46 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $80.28 million which missed the analyst consensus estimate of $93.02 million by 13.69 percent. This is a 24.31 percent decrease over sales of $106.07 million the same period last year.